KIRKLAND, Wash.--(BUSINESS WIRE)--ProteoTech, Inc., announced today that Dr. Alan Snow, President and Chief Scientific Officer, made two different presentations representing ProteoTech technologies at the 12th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2015) held in Nice, France, March 18–22, 2015. Dr. Snow gave an oral presentation on Saturday, March 21, 2015 entitled:
“PD-61-W3 (Synuclere™) is a Novel Small Molecule and Clinical Candidate for Treatment of Alpha-Synuclein Aggregate Accumulation in Parkinson’s Disease and Other Synucleinopathies”
The oral presentation reviewed pre-clinical and animal model data that demonstrate that the small molecule PD-61-W3 (also known as Synuclere™) is a potent inhibitor and reducer of alpha-synuclein aggregates in the brains of transgenic animals that over-produce alpha-synuclein in neurons. Synuclere™ treatment not only reduced alpha-synuclein aggregates in neurons in transgenic mice, but also markedly improved the motor dysfunction (trouble in walking and motor function) that occurs in these animals as they accumulate alpha-synuclein in the brain. Alpha-synuclein aggregation occurs in neurons as Lewy bodies in Parkinson’s disease and related disorders and is an important therapeutic target. Synuclere™ is an effective small molecule targeting alpha-synuclein accumulation as a treatment for Parkinson’s disease and related disorders (such as the orphan disease Multiple System Atrophy).
In a poster presented on Friday, March 20, 2015, ProteoTech gave an update on its program related to small molecule development for the treatment of tau aggregation that occurs in Alzheimer’s disease and other tauopathies. ProteoTech’s presentation was entitled:
“Development of the Novel Small Molecule Tau Aggregation Inhibitors, PTI-51-CH3 (TauPro™) and PTI-80 for the Treatment of Tauopathies”
ProteoTech identified and developed these two small molecules (that represent new chemical entities) that potently inhibited tau proteins to form β-sheet-containing fibrils, and/or disrupted preformed tau fibrils in vitro. Current testing of TauPro™ and PTI-80 involve the use of transgenic mice that develop neurofibrillary tangles in their brains as they age. These lead compounds are in development for potent inhibition and disruption of tau protein tangles, a key pathological hallmark in Alzheimer’s disease and other tauopathies such as the rare “orphan” disease Progressive Supranuclear Palsy (PSP).
About ProteoTech: ProteoTech is a privately-held, therapeutic development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTech’s lead small molecule compound, Systebryl™ (PTI-110), will soon be entering a Phase 1/2 proof-of-concept clinical trial in patients with AL (immunoglobulin light chain) amyloidosis (an “orphan” disease). Other drugs in the ProteoTech pipeline include a small molecule drug inhibitor for TTR (transthyretin) amyloidosis; a small molecule drug for dialysis-related amyloidosis; Synuclere™, a small molecule drug inhibitor of alpha-synuclein accumulation (for Multiple System Atrophy and other synucleinopathies such as Parkinson’s disease); and TauPro™ and PTI-80, small molecule drugs that target tau protein aggregates involved in Alzheimer’s disease and the orphan disease Progressive Supranuclear Palsy.
